Product lifecycle solutions
We deliver intelligent insights through the pharmaceutical product lifecycle
From early-stage commercial opportunity assessment and market understanding, forecasting and landscaping, through ideation, concept testing, product and brand development, profiling, communications testing, launch and post-launch tracking, we can support pharma with intelligent market research and consulting solutions through the lifecycle of the brand.
Senior level involvement
Our large, senior team of over 40 Directors are involved at every stage of the project.
High quality research
Our outputs answer the key business questions with a clear, direct recommendation, supported by the research evidence.
Communication and flexibility
We keep clients informed through weekly updates and respond quickly to needs and deadlines.
A creative approach
We offer custom approaches, not branded solutions, so our research design is always creative and fresh.
- Some example case studiesHow Paediatricians and GPs revealed key insights to help develop a science story for a child nutritional supplement
The challenge:Our client needed to develop a science story in order to increase uptake for their child nutritional supplement. Research was required in order to define the patient target, frame the challenge of growth delays to be an effective call to action, articulate objectives for the product and the best way to express its value proposition. The solution:We conducted a mix of “workshop-style” focus groups…read more »How we helped our client to understand the opportunities across Asia and other emerging markets using interactive outputs
The challenge:Our client needed to understand why the use of statins in type 2 diabetes patients in South Korea, China, Thailand and other developing countries is low / sub-optimal. Research was required to understand the diabetic patient journey in order to assess the opportunities to expand HCP knowledge on the importance of lipid lowering for type 2 diabetes patients. The client also wanted to explore…read more »How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
The challenge: Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful…read more »
- Our latest white papersAre dual ARVs the new frontier in a maturing HIV market?
Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.read more »Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations
In this paper we examine the differences between behavioural and attitudinal approaches to segmentation and outline how integration of the two can best be achieved to strengthen segmentation solutionsread more »